Variable | Number positive/total (%) | p value vs normala,b | Other (p value)a,b |
---|---|---|---|
All samples | |||
Normal breast | 24/57 (42) | ||
Hyperplasia | 11/20 (55) | 0.2308 | |
Ductal carcinoma | 33/150 (22) | 0.0038 | |
Grade | |||
1 | 4/34 (12) | 0.0019 | |
2 | 25/102 (25) | 0.0174 | |
3 | 2/10 (20) | 0.1665 | |
Stage | |||
I | 0/6 (0) | 0.0480 | I/II vs III/VI (0.0287) |
II | 29/105 (28) | 0.0452 | |
I/II | 29/111 (26) | 0.0273 | |
III | 4/33 (12) | 0.0024 | |
IV | 0/6 (0) | 0.0480 | |
III/IV | 4/39 (10) | 0.0005 | |
Tumor invasion | |||
T1 | 2/8 (25) | 0.3015 | T1/2 vs T3/4 (0.0143) |
T2 | 25/89 (28) | 0.0587 | |
T1/T2 | 27/97 (28) | 0.0512 | |
T3 | 4/28 (14) | 0.0084 | |
T4 | 2/25 (8) | 0.0015 | |
T3/T4 | 6/53 (11) | 0.0002 | |
Nodal status | |||
N0 | 25/98 (26) | 0.0254 | 0 vs 1 (0.1625) |
N1 | 6/38 (16) | 0.0057 | 0/1 vs 2/3 (0.3657) |
N2 | 2/12 (17) | 0.0894 | |
N3 | 0/2 (0) | 0.3477 | |
Metastasis | |||
M0 | 33/146 (23) | 0.0052 | M0 vs M1 (0.3659) |
M1 | 0/4 (0) | 0.1266 | |
Estrogen receptor status | |||
ER+ | 13/63 (21) | 0.0093 | ER+ vs ER− (0.5000) |
ER− | 15/78 (19) | 0.0035 | |
Progesterone receptor status | |||
PR+ | 11/44 (25) | 0.0562 | PR+ vs PR− (0.2177) |
PR− | 17/96 (18) | 0.0011 | |
HER2 status | |||
HER2- | 4/32 (13) | 0.0031 | HER2− vs HER2+ (0.1702) |
HER2+ | 24/108 (22) | 0.0068 | |
Age/menopausal status | |||
<48 | 21/71 (30) | 0.0988 | <48 vs ≥48 (0.0268) |
48–54 | 6/37 (16) | 0.0040 | <51 vs ≥51 (0.0218) |
>54 | 6/42 (14) | 0.0024 | <54 vs ≥54 (0.0480) |
<48 vs ≥54 (0.0263) |